Investor Presentaiton
GSK
Sales (£m)
Performance: 12% HIV growth in 2022 driven by innovation portfolio
1,000
Momentum building across portfolio
Growth driven by Dovato and long-acting regimens
.
48%
800
44%
41%
38%
34%
600
29%
27%
25%
400
200
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022
Apretude
Juluca
Dovato
Rukobia
Cabenuva
Innovation as a % of total HIV sales
.
.
Sales of £5.7bn in 2022 driven by two drug
regimens and long-acting injectable portfolio
Innovation sales of £2.5bn in 2022 - 43% of HIV
portfolio
Dovato sales of £1.4bn on track to become our
#1 HIV product
Cabenuva sales of £340m reflecting strong
patient demand - now launched in all major
markets
Apretude sales of £41m - growing strongly in US
SOLAR study and further pipeline data to be
presented at CROI in February
19View entire presentation